It has been found that Sparcl1 is frequently downregulated in many cancers, including colorectal carcinoma (14), prostate cancers (15), pancreatic cancer (16), etc., suggesting its potential role as a tumor suppressor (17). Here, SPARCL1 is linked to pancreatic neoplasm.